24-10-2013 дата публикации
Номер: US20130281482A1
The invention provides novel nicotinic acetylcholine receptor agonists, for example, phantasmidine and derivatives thereof, for example a compound of formula (I). Also disclosed are methods of treating disorders responsive to nicotinic acetylcholine receptor agonists such as Alzheimer's disease, schizophrenia, Myasthenia Gravis, Tourette's syndrome, Parkinson's disease, epilepsy, pain, and cognitive dysfunction by treatment with the nicotinic acetylcholine for agonists. 1. Phantasmidine , or phantasmidine in isolated or purified form , an enantiomer thereof , stereoisomer thereof , racemic mixtures thereof , or a pharmaceutically acceptable salt thereof.3. The compound claim 2 , enantiomer thereof claim 2 , stereoisomer thereof claim 2 , racemic mixtures thereof claim 2 , or salt of claim 2 , wherein the compound has Formula I.4. The compound claim 3 , enantiomer thereof claim 3 , stereoisomer thereof claim 3 , racemic mixtures thereof claim 3 , or salt of claim 3 , wherein m is 1 claim 3 , n is 0 claim 3 , p is 2 claim 3 , W is a bond claim 3 , and Z is 0.5. The compound claim 4 , enantiomer thereof claim 4 , stereoisomer thereof claim 4 , racemic mixtures thereof claim 4 , or salt of claim 4 , wherein Ris selected from the group consisting of hydrogen claim 4 , C-Calkyl claim 4 , C-Calkenyl claim 4 , C-Calkynyl claim 4 , C-Ccycloalkyl claim 4 , C-Ccycloalkenyl claim 4 , C-Carylalkyl claim 4 , C-Caryl claim 4 , heterocyclyl claim 4 , heteroaryl claim 4 , and RCO.6. The compound claim 4 , enantiomer thereof claim 4 , stereoisomer thereof claim 4 , racemic mixtures thereof claim 4 , or salt of claim 4 , wherein Ris selected from the group consisting of hydrogen claim 4 , C-Calkyl claim 4 , C-Calkenyl claim 4 , C-Calkynyl claim 4 , and RCO.7. The compound claim 6 , enantiomer thereof claim 6 , stereoisomer thereof claim 6 , racemic mixtures thereof claim 6 , or salt of claim 6 , wherein Ris hydrogen or C-Calkyl.8. The compound claim 7 , enantiomer thereof claim 7 , ...
Подробнее
